Women's Weight Management
FDA-approved GLP-1 medications for sustained weight loss in women. Semaglutide and tirzepatide address hormonal and metabolic drivers. Same-day physician evaluation, all 50 states.
Prescription required. Provider determines if clinically appropriate.
Women's weight management online — GLP-1 program
FDA-approved GLP-1 receptor agonists (semaglutide as Wegovy®, tirzepatide as Zepbound®) address hormonal and metabolic drivers of weight, producing 15-22% body-weight loss over a year — substantially more than older interventions. Eligibility is typically BMI 30+, or BMI 27+ with a qualifying condition. The FirstCall platform connects you with an independent, board-certified physician for evaluation and, when clinically appropriate, a prescription sent to a pharmacy of your choice.
BMI ≥30, or ≥27 with a qualifying comorbidity
semaglutide (Wegovy®), tirzepatide (Zepbound®)
15-22% of body weight over 12+ months on tirzepatide
Educational content. Last clinically reviewed by the FirstCall Clinical Editorial Board, June 2026. The FirstCall platform provides access to independent, licensed physicians; final clinical decisions rest with the prescribing physician.
Why weight management is different for women — and what GLP-1 medications do
Understanding the condition makes the treatment decision clearer.
Women face distinct metabolic challenges throughout life that make sustained weight loss particularly difficult. PCOS causes insulin resistance and weight gain that responds poorly to diet alone. Perimenopause shifts fat distribution toward the abdomen and reduces metabolic rate. Thyroid dysfunction — more common in women — reduces energy expenditure. GLP-1 medications address the hormonal and metabolic drivers of weight gain, not just caloric intake — making them effective where diet and exercise alone have failed.
Key insight: GLP-1 medications do not help women lose weight by reducing willpower. They address a specific hormonal deficit — inadequate GLP-1 signaling after meals — that is present in people with obesity. This is a biological intervention, not a behavioral one.
Weight management for women is hormonal — not a willpower deficit
The hormones that regulate hunger and metabolism work differently in women with obesity, PCOS, or menopausal changes. GLP-1 medications correct a specific hormonal deficit — they are not shortcuts. They represent the most significant advancement in metabolic medicine in decades, producing average weight loss of 15–22% in clinical trials alongside diet and exercise. For women who have struggled with weight despite genuine effort, these medications address the biological reality.
What to expect
Set realistic expectations and stay consistent — results take time.
Most women notice significantly reduced appetite within the first 2–4 weeks of treatment.
Average weight loss of 5–8% of body weight. Metabolic improvements begin.
Significant body composition improvements. Energy and metabolic markers improving.
Maximum average weight loss achieved. Maintained with continued treatment.
GLP-1 medications address the specific metabolic challenges women face
Women with PCOS experience insulin resistance that drives both weight gain and androgen excess. GLP-1 medications improve insulin sensitivity — reducing the metabolic driver of PCOS-related weight gain and often improving cycle regularity. For perimenopausal women, GLP-1 medications offset the metabolic slowdown and abdominal fat redistribution that occurs as estrogen declines. These are not generic weight loss medications — they address the specific hormonal context of women's weight challenges.
The science behind women's weight management
Evidence-based treatment addresses the underlying mechanism — not just the symptoms.
GLP-1 receptor agonists mimic the GLP-1 hormone released after eating — suppressing appetite signals to the brain, slowing gastric emptying, and improving insulin sensitivity. The combined effect is dramatically reduced caloric intake without hunger or food preoccupation. Weekly injection. Dose escalated gradually to minimize side effects.
Semaglutide (Wegovy®) is a GLP-1 receptor agonist producing average 15% weight loss. Tirzepatide (Zepbound®) targets both GLP-1 and GIP receptors — producing average 20–22% weight loss in trials. Both are weekly injections. Tirzepatide typically produces superior weight loss results. Your physician will recommend based on your medical profile and availability.
FDA approval covers adults with BMI ≥30 (obese) or BMI ≥27 (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, or PCOS. The physician you're connected with will assess eligibility and recommend the appropriate medication based on your clinical profile and insurance coverage.
Treatments that work together
Comprehensive care often combines complementary treatments for better outcomes.
Weight management as a long-term health relationship.
GLP-1 medications work as part of an ongoing care relationship. Dose escalation is gradual — typically over 16–20 weeks — to minimize side effects. Regular physician check-ins monitor progress and adjust dosing. FirstCall provides the ongoing access needed for proper long-term GLP-1 management.
How it works
From first visit to prescription in as little as 15 minutes.
Brief online health questionnaire from your phone. Takes 5–10 minutes.
A board-certified physician reviews privately and recommends your treatment — same day.
Sent to your pharmacy or shipped discreetly in plain, unmarked packaging.
Women's weight management — evaluation and pricing
Free consultation. Insurance assessment included. Cash pay options available.
How we’re different
FirstCall was built to make women’s health care genuinely accessible.
No 3-week appointment waitlists. Board-certified physicians prescribe the same day — often within the hour.
HIPAA-protected. Plain unmarked packaging. No waiting room, no front desk, no one who knows you.
One membership covers your whole household — women’s, men’s, senior care, and pets.
Trusted telehealth provider since 2017. Board-certified physicians licensed in your state.
*Based on publicly available competitor information.
Frequently asked questions
Clear answers about women's weight management and how FirstCall works.
GLP-1 medications should not be used by women with a personal or family history of medullary thyroid carcinoma or MEN 2. Contraindicated in pregnancy — use effective contraception and discontinue at least 2 months before trying to conceive. Common side effects include nausea, vomiting, and GI symptoms especially during dose escalation. Pancreatitis has been reported — seek immediate medical care for severe abdominal pain. Read full prescribing information ›
Related treatments
Other women’s health treatments available through FirstCall.
